Medical Doctor, Padua University
Dr. Tiziano founded the Department of Hematology at “Ospedali Riuniti di Bergamo,” where he was the Director from 1981 to 2008 and chief of the Department of Oncology and Hematology. He was an adjunct professor at the Hematology School of the University of Milan (State and Bicocca University) and Verona University. He has served as Chairman of the International Society of Thrombosis and Hemostasis and was former President of the Italian Society of Hematology.
Currently, he leads the European-Leukemia-Net WP-9 on Myeloproliferative Disorders. He is one of the founders of the NIH (US) Myeloproliferative Disorders Consortium. He was a member of the Good Governance Committee of the European Hematology Association (EHA).
The research interest has focused on three aspects. 1. Hereditary or acquired hemorrhagic and thrombotic diseases. 2. Malignant, acute, and chronic hematological diseases; 3. Myeloproliferative neoplasms. After his retirement (2008), in collaboration with the Directors of Ospedali Riuniti di Bergamo, he helped to create the Foundation for Clinical Research (FROM).
Since 2008, in addition to contributing to the research of our hospital institution, he has promoted an international clinical research area on chronic myeloproliferative diseases and clonal hematopoiesis associated with thrombosis and cancer in the general population.
The most cited articles refer to the Lupus anticoagulant syndrome, the hemostatic disturbances and therapy of acute leukemia, and the optimization of diagnosis, prognosis, and treatment of myeloproliferative neoplasms. He has been the principal investigator in several academic clinical trials published in the New England Journal of Medicine: ECLAP, CYTO-PV, Low-RISK PV, and Hydroxyurea in ET (Bergamo trial).
Prof. Barbui received the gold medal from the Bergamo City Hall for his continued dedication to the care of patients with malignant hematologic diseases and for his contribution to the advancement of hematology science. During the European Hematology Association (EHA) meeting in Stockholm (2013), he received the “Jean-Bernard Award” for his contribution to the optimization of diagnosis, prognosis, and therapy of the Myeloproliferative neoplasms and for establishing international networks for clinical research in Hematology.
He published more than 700 peer-reviewed papers. Of these, the most important for this grant application are:
He has been the principal investigator in several academic clinical trials published in the New England Journal of Medicine: ECLAP, CYTO-PV, Low-RISK PV, and Hydroxyurea in ET (Bergamo trial). The American Society of Hematology (ASH) and the European Hematology Association (EHA) have invited him several times as an official speaker for their educational programs on chronic myeloproliferative diseases. He organizes annual international meetings on behalf of the European Leukemia Net (ELN) in Mannheim, Germany. He has presented numerous oral communications in several meetings and had the honor of being selected to present the results of a clinical trial at the plenary session of ASH in San Diego, California (2012).
